EZH2 and neoplasm: Epigenetic modulating capacity and the anti-tumor response of administering EZH2 inhibitors, SHR2554, with an anti-PD-L1 antibody, SHR1701, is being tested in a trial involving patients with metastatic solid tumors and resistant B-cell lymphomas (NCT04407741).